

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM463149

| | | | |
|---|---|------------------------------------|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| BIODESIX, INC. | | 02/23/2018 | Corporation: DELAWARE |
| RECEIVING PARTY DATA | | | |
| Name: | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, as collateral agent | | |
| Street Address: | 777 THIRD AVENUE, 25TH FLOOR | | |
| City: | NEW YORK | | |
| State/Country: | NEW YORK | | |
| Postal Code: | 10017 | | |
| Entity Type: | Limited Partnership: DELAWARE | | |
| PROPERTY NUMBERS Total: 15 | | | |
| Property Type | Number | Word Mark | |
| Registration Number: | 5363516 | BIODESIX LUNG REFLEX | |
| Serial Number: | 87328186 | VERISTRAT LIQUID BIOPSY | |
| Serial Number: | 87328149 | GENESTRAT LIQUID BIOPSY | |
| Serial Number: | 87629867 | ONCOSTRAT | |
| Serial Number: | 87586059 | BIODESIX LUNG REFLEX | |
| Serial Number: | 86588401 | IMMUNOSTRAT | |
| Registration Number: | 5087240 | DIAGNOSTIC CORTEX | |
| Registration Number: | 5042185 | GENESTRAT | |
| Registration Number: | 4588638 | WE THINK FORWARD | |
| Registration Number: | 4660213 | DEEP MALDI | |
| Registration Number: | 4221851 | GUIDING THE WAY | |
| Registration Number: | 4223067 | BIODESIX: MAKING MEDICINE PERSONAL | |
| Registration Number: | 3655592 | PROTS | |
| Registration Number: | 3470295 | VERISTRAT | |
| Registration Number: | 3483094 | BIODESIX | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | 8585506420 | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |

CH \$390.00 5363516

Phone: 858-550-6433
Email: jmfitzpatrick@cooley.com
Correspondent Name: JENNIFER FITZPATRICK
Address Line 1: C/O COOLEY LLP
Address Line 2: 4401 EASTGATE MALL
Address Line 4: SAN DIEGO, CALIFORNIA 92121

ATTORNEY DOCKET NUMBER: 330829-107

NAME OF SUBMITTER: JENNIFER FITZPATRICK

SIGNATURE: /JENNIFER FITZPATRICK/

DATE SIGNED: 02/23/2018

Total Attachments: 14

source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page1.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page2.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page3.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page4.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page5.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page6.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page7.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page8.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page9.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page10.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page11.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page12.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page13.tif
source=Innovatus - Biodesix - Intellectual Property Security Agreement (executed)#page14.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the Effective Date by and between INNOVATUS LIFE SCIENCES LENDING FUND I, LP, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (in such capacity, the "Collateral Agent") and BIODESIX, INC. ("Grantor").

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

BIODESIX, INC.

2970 Wilderness Place, Suite 100
Boulder, CO 80301
Attn: Chief Financial Officer

By: 
Name: Robin Harper Cowie
Title: Chief Financial Officer

COLLATERAL AGENT:

Address of Lender:

INNOVATUS LIFE SCIENCES LENDING FUND
I, LP

By: Innovatus Life Sciences GP, LP
Its: General Partner

777 Third Avenue, 25th Floor
New York, NY 10017

By: _____
Name: _____
Title: _____

{Signature Page to Intellectual Property Security Agreement}

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

BIODESIX, INC.

2970 Wilderness Place, Suite 100
Boulder, CO 80301
Attn: Chief Financial Officer

By: _____
Name: _____
Title: _____


COLLATERAL AGENT:

Address of Lender:

INNOVATUS LIFE SCIENCES LENDING FUND
I, LP

By: Innovatus Life Sciences GP, LP
Its: General Partner

777 Third Avenue, 25th Floor
New York, NY 10017

By: 
Name: Andrew Robien
Title: Authorized Signatory

{Signature Page to Intellectual Property Security Agreement}

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None.

EXHIBIT B

Patents

(See attached)

| Title | Country | Region / ID # | Patent Status | Serial No. | Filing Date | Parent No. | Abandoned / Active | Issue Date |
|---|---------|---------------|--------------------------|-----------------------------|-------------|------------|--------------------|------------|
| Method to automatically identify peak and monochromatic peaks in | FR | US | (11) Expired / Abandoned | 80489032 | 7/7/2002 | | Abandoned | |
| Method to automatically identify peak and monochromatic peaks in mass spectral data for biomolecular interactions | US | US | (11) Expired / Abandoned | 10/887138 | 7/7/2004 | | Abandoned | |
| Continuation of 04-773 US | US | US | (11) Expired / Abandoned | 10/138,313 | 7/21/2004 | | Abandoned | |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | AT | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and system for determining whether a drug will be effective on a patient with a disease | AU | Foreign | (10) Issued / Granted | 2007243644 | 3/26/2007 | 2007243644 | Active | 9/2/2010 |
| VeriStrat for CRC | AU | Foreign | (11) Expired / Abandoned | 2009338173 | 11/20/2009 | 2009338173 | Abandoned | 5/31/2012 |
| VeriStrat for SCCRN | AU | Foreign | (11) Expired / Abandoned | 2009338174 | 11/20/2009 | 2009338174 | Abandoned | 5/31/2012 |
| Probabilistic K-nearest neighbor classifier for blood-based samples | AU | Foreign | (10) Issued / Granted | 2010201206 | 3/25/2010 | 2010201206 | Active | 6/21/2012 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | BE | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for NSCLC | CA | Foreign | (10) Issued / Granted | CA 2647871 | 3/26/2007 | 2647871 | Active | 3/11/2014 |
| VeriStrat for CRC | CA | Foreign | (11) Expired / Abandoned | 2744384 | 11/20/2009 | | Abandoned | |
| VeriStrat for SCCRN | CA | Foreign | (11) Expired / Abandoned | 2744313 | 8/27/2010 | | Abandoned | |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | CH | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | DE | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for NSCLC | EU | Foreign | (10) Issued / Granted | 7754043.3 EP20070754043 | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for CRC | GB | Foreign | (11) Expired / Abandoned | 2347261 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for CRC | DE | Foreign | (11) Expired / Abandoned | 2347261 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for CRC | ES | Foreign | (11) Expired / Abandoned | 2347261 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for CRC | FR | Foreign | (11) Expired / Abandoned | 2347261 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for CRC | GB | Foreign | (11) Expired / Abandoned | 2347261 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for CRC | IT | Foreign | (11) Expired / Abandoned | 2347261 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for CRC | SE | Foreign | (11) Expired / Abandoned | 2347261 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for CRC | EU | Foreign | (11) Expired / Abandoned | 0729826.7 EP20060754043 | 11/20/2009 | 2347261 | Abandoned | 8/15/2012 |
| VeriStrat for SCCRN | CH | Foreign | (11) Expired / Abandoned | | 11/20/2009 | 2247954 | Abandoned | |
| VeriStrat for SCCRN | DE | Foreign | (11) Expired / Abandoned | | 11/20/2009 | 2247954 | Abandoned | |
| VeriStrat for SCCRN | ES | Foreign | (11) Expired / Abandoned | | 11/20/2009 | 2247954 | Abandoned | |
| VeriStrat for SCCRN | FR | Foreign | (11) Expired / Abandoned | | 11/20/2009 | 2247954 | Abandoned | |
| VeriStrat for SCCRN | GB | Foreign | (11) Expired / Abandoned | | 11/20/2009 | 2247954 | Abandoned | |
| VeriStrat for SCCRN | IT | Foreign | (11) Expired / Abandoned | | 11/20/2009 | 2247954 | Abandoned | |
| VeriStrat for SCCRN | SE | Foreign | (11) Expired / Abandoned | | 11/20/2009 | 2247954 | Abandoned | |
| VeriStrat for SCCRN | EU | Foreign | (11) Expired / Abandoned | 08774394.3 EP20060754043 | 11/20/2009 | 2247954 | Abandoned | 7/13/2011 |
| Probabilistic K-nearest neighbor classifier for blood-based samples | EU | Foreign | (11) Expired / Abandoned | 10013344.8 EP20070754043 | 3/25/2010 | 20071326 | Abandoned | |
| NSCLC VeriStrat - Laboratory test processing center | EU | Foreign | (08) Examination Year 3+ | EP20100003344 | 3/26/2010 | | Active | |

| Title | Country | Region / ID | Patent Status | Serial No. | Filing Date | Pub. No. | Abandoned / Active | Issue Date |
|--|---------|-------------|--------------------------|-----------------|-------------|------------|--------------------|------------|
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | ES | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | FR | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | GB | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for NSCLC | HK | Foreign | (10) Issued / Granted | 9105283.6 | 3/26/2007 | HK1126416 | Active | 3/26/2017 |
| VeriStrat for CRC | HK | Foreign | (11) Expired / Abandoned | HK1156896 | 10/14/2011 | | Abandoned | 4/11/2013 |
| VeriStrat for NSCLC | HK | Foreign | (11) Expired / Abandoned | 11164025.6 | 3/26/2007 | | Abandoned | |
| VeriStrat for LCCIN | HK | Foreign | (11) Expired / Abandoned | 1148073 | 7/3/2011 | 1148073 | Abandoned | 12/30/2013 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | HK | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | IE | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for CRC | IL | Foreign | (11) Expired / Abandoned | 211944 | 11/20/2009 | 211944 | Abandoned | 3/1/2014 |
| VeriStrat for LCCIN | IL | Foreign | (11) Expired / Abandoned | 211943 | 3/24/2011 | 211943 | Active | 1/31/2014 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | IT | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for NSCLC | JP | Foreign | (10) Issued / Granted | 2009502923 | 3/26/2007 | 4963721 | Active | 4/6/2012 |
| VeriStrat for CRC | JP | Foreign | (11) Expired / Abandoned | 2011-50456 | 11/20/2009 | 496348 | Abandoned | 5/13/2013 |
| VeriStrat for SCCIN | JP | Foreign | (11) Expired / Abandoned | 2010-548752 | 11/20/2009 | 5025602 | Abandoned | 6/11/2012 |
| VeriStrat for CRC | JP | Foreign | (11) Expired / Abandoned | 10-2011-7007641 | 11/20/2009 | 10-2131211 | Abandoned | 8/30/2013 |
| Method and System for Determining Whether A Drug Will Be Effective on a Patient with a Disease | KR | Foreign | (10) Issued / Granted | 10-2008-7026830 | 3/26/2010 | 10-1068732 | Active | 8/23/2011 |
| VeriStrat for SCCIN | KR | Foreign | (11) Expired / Abandoned | 10-2010-7013621 | 7/28/2011 | 10-1121407 | Abandoned | 7/10/2012 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | NL | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for NSCLC | NO | Foreign | (10) Issued / Granted | 20084615 | 3/26/2007 | | Active | |
| VeriStrat | PCI | Foreign | (11) Expired / Abandoned | PCI/US07/007467 | 3/26/2007 | | Abandoned | |
| VeriStrat for CRC | PCI | Foreign | (11) Expired / Abandoned | PCI/US09/062657 | 11/20/2009 | | Abandoned | |
| VeriStrat for LCCIN | PCI | Foreign | (11) Expired / Abandoned | PCI/US09/062663 | 11/20/2009 | | Abandoned | |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | PL | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | PT | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | SE | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| Method and System for Determining Whether a Drug will be Effective on a Patient with a Disease | TR | Foreign | (10) Issued / Granted | | 3/26/2007 | 2007434 | Active | 2/17/2016 |
| VeriStrat for CRC | TW | Foreign | (11) Expired / Abandoned | 08142101 | 11/21/2006 | 1308497 | Abandoned | 1/21/2012 |
| VeriStrat for LCCIN | TW | Foreign | (11) Expired / Abandoned | 08143182 | 11/16/2006 | 030140182 | Abandoned | 7/11/2012 |
| VeriStrat for NSCLC | US | US | (10) Issued / Granted | 11/396328 | 3/31/2006 | 7736905 | Active | 6/15/2010 |
| VeriStrat for CRC | US | US | (10) Issued / Granted | 12/321394 | 1/20/2009 | 7,858,390 | Active | 12/28/2010 |

| Title | Country | Category / ID | Status / Status | Amount / Amt. | Filing Date | Amount / Amt. | Abandoned / Active | End Date |
|--|---------|---------------|--------------------------|-----------------------------|-------------|---------------|--------------------|------------|
| VeriStrat for SCCHN | US | US | (10) Issued / Granted | 12/321393 | 1/20/2009 | 7,867,775 | Active | 1/11/2011 |
| VeriStrat for NSCLC with EGFR-Is | US | US | (10) Issued / Granted | 12/321392 | 1/20/2009 | 7,858,389 | Active | 12/28/2010 |
| VeriStrat NSCLC lab test processing center | US | US | (10) Issued / Granted | 12/661129 | 3/10/2010 | 7879620 | Active | 2/1/2011 |
| Method and system for determining whether a drug will be effective on a patient with a disease | US | US | (11) Expired / Abandoned | 12/661124 | 3/10/2010 | 8097469 | Abandoned | 1/17/2012 |
| VeriStrat lab test center, generic to cancer, drugs | US | US | (09) Allowance | 12/806137 | 8/6/2010 | 9,824,182 | Active | 11/21/2017 |
| Preprocessing for VeriStrat | US | US | (10) Issued / Granted | 13/373,336 | 11/11/2011 | 9152758 | Active | 2/9/2016 |
| Preprocessing for VeriStrat | US | US | (11) Expired / Abandoned | 13/434,133 | 3/26/2012 | | Abandoned | |
| Mass spec peak ID methods | US | US | (11) Expired / Abandoned | 10/837436 | 07/07/2004 | | Abandoned | |
| Probabilistic KNN classifier | PRO | US | (11) Expired / Abandoned | 01/063950 | 7/15/2008 | | Abandoned | |
| Probabilistic KNN classifier | US | US | (10) Issued / Granted | 12/218519 | 7/15/2008 | 8,024,282 | Active | 9/20/2011 |
| VeriStrat for Treatment Monitoring | PRO | US | (11) Expired / Abandoned | 01/191332 | 3/13/2009 | | Abandoned | |
| VeriStrat for Treatment Monitoring | US | US | (10) Issued / Granted | 12/584594 | 9/8/2009 | 7,906,342 | Active | 3/15/2011 |
| VeriStrat for Treatment Monitoring | US | US | (10) Issued / Granted | 12/931,324 | 1/27/2011 | 8,119,418 | Active | 2/21/2012 |
| VeriStrat for Treatment Monitoring | US | US | (10) Issued / Granted | 12/931,322 | 1/27/2011 | 8,119,417 | Active | 2/21/2012 |
| VeriStrat for Treatment Monitoring | US | US | (11) Expired / Abandoned | 12/931,321 | 1/27/2011 | | Abandoned | |
| VeriStrat for Treatment Monitoring | US | US | (10) Issued / Granted | 13/313,791 | 12/7/2011 | 8,586,379 | Active | 11/19/2013 |
| VeriStrat for Treatment Monitoring | US | US | (10) Issued / Granted | 13/313,838 | 12/7/2011 | 8,586,380 | Active | 11/19/2013 |
| Lung Cancer Detection | PRO | US | (01) Unfiled | TBD | | | Active | |
| VeriStrat Mechanism of Action | RU | Foreign | (11) Expired / Abandoned | 2011215065 | 2/22/2011 | 2011215065 | Abandoned | 7/21/2014 |
| VeriStrat Mechanism of Action | AU | Foreign | (11) Expired / Abandoned | 2014202716 | 5/19/2014 | | Abandoned | |
| VeriStrat Mechanism of Action | CA | Foreign | (11) Expired / Abandoned | 2750716 | 2/22/2011 | | Abandoned | |
| VeriStrat Mechanism of Action | CN | Foreign | (11) Expired / Abandoned | 201180310826 | 2/22/2011 | | Abandoned | |
| VeriStrat Mechanism of Action | EU | Foreign | (11) Expired / Abandoned | 112478083 EP201107472001 | 2/22/2011 | | Abandoned | |
| VeriStrat Mechanism of Action | JP | Foreign | (11) Expired / Abandoned | 2012555061 | 2/22/2011 | | Abandoned | |
| VeriStrat Mechanism of Action | JP | Foreign | (11) Expired / Abandoned | 2012322648 | 6/17/2010 | | Abandoned | |
| VeriStrat Mechanism of Action | KR | Foreign | (11) Expired / Abandoned | 10-2012-7024976 | 2/22/2011 | 10-1956726 | Abandoned | 9/23/2015 |

| Title | Country | Foreign/ US | Patent Status | Serial No. | Filing Date | Parent No. | Abandoned/ Active | Issue Date |
|--|---------|-------------|---------------------------------|----------------------|-------------|------------|-------------------|------------|
| VeriStrat Mechanism of Action | PCT | Foreign | (11) Expired / Abandoned | PCT/AU55011,1003,823 | 2/22/2011 | | Abandoned | |
| VeriStrat Mechanism of Action | PRC | US | (11) Expired / Abandoned | 61,339,939 | 2/24/2010 | | Abandoned | |
| VeriStrat Mechanism of Action | TW | Foreign | (11) Expired / Abandoned | 106106286 | 6/21/2011 | | Abandoned | |
| VeriStrat Mechanism of Action | US | US | (11) Expired / Abandoned | 12,732,295 | 2/22/2011 | | Abandoned | |
| VeriStrat Mechanism of Action | US | US | (11) Expired / Abandoned | 14,725,283 | 6/4/2014 | | Abandoned | |
| Mass spec peak ID methods | | | (02) Merged Into Another Filing | N/A | | | Active | |
| Mass spec peak ID methods | | | (02) Merged Into Another Filing | N/A | | | Active | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | JP | Foreign | (11) Expired / Abandoned | 201220951H | 1/24/2012 | 201220951H | Abandoned | 11/5/2015 |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | CA | Foreign | (11) Expired / Abandoned | 2524877 | 1/24/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | GB | Foreign | (11) Expired / Abandoned | 201281006861.5 | 1/24/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | RU | Foreign | (11) Expired / Abandoned | 10754073.3 | 1/24/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | HK | Foreign | (11) Expired / Abandoned | 14104961.3 | 5/27/2014 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | JP | Foreign | (11) Expired / Abandoned | 2014-110790 | 1/24/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | KR | Foreign | (11) Expired / Abandoned | 10-2013-7621660 | 1/24/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | PCT | Foreign | (11) Expired / Abandoned | PCT/US12/00044 | 1/24/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | PRC | US | (11) Expired / Abandoned | 61,487,575 | 1/28/2011 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | TW | Foreign | (11) Expired / Abandoned | 10110291 | 1/24/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | TW | Foreign | (11) Expired / Abandoned | 106106286 | 1/30/2012 | | Abandoned | |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | US | US | (10) Issued / Granted | 13/356,730 | 1/24/2012 | 8,914,238 | Active | 12/16/2014 |
| Test for Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients | US | US | (10) Issued / Granted | 13/741,634 | 1/15/2013 | 9,254,120 | Active | 10/6/2015 |

| Title | Country | Region / I-P | Patent Status | Serial No. | Filing Date | Parent No. | Abandoned / Active | Issue Date |
|---|---------|--------------|---------------------------------|-----------------------------|-------------|------------|--------------------|------------|
| VenStrat for predicting benefit from platinum-based chemotherapy agents | AU | Foreign | (11) Expired / Abandoned | 2013287261 | 3/15/2013 | | Abandoned | |
| VenStrat for predicting benefit from platinum-based chemotherapy agents | CA | Foreign | (11) Expired / Abandoned | 2878441 | 3/15/2013 | | Abandoned | |
| VenStrat for predicting benefit from platinum-based chemotherapy agents | EU | Foreign | (11) Expired / Abandoned | 13714122.3 EP20130714324 | 3/15/2013 | | Abandoned | |
| VenStrat for predicting benefit from platinum-based chemotherapy agents | HK | Foreign | (11) Expired / Abandoned | PCT/US2013/022010 | 3/15/2013 | | Abandoned | |
| VenStrat for predicting benefit from platinum-based chemotherapy agents | PRO | US | (11) Expired / Abandoned | 617668777 | 7/5/2012 | | Abandoned | |
| VenStrat for predicting benefit from platinum-based chemotherapy agents | TW | Foreign | (11) Expired / Abandoned | 102112561 | 4/9/2011 | | Abandoned | |
| VenStrat for predicting benefit from platinum-based chemotherapy agents | US | US | (10) Issued / Granted | 13/836,064 | 3/15/2013 | 8,718,996 | Active | 5/6/2014 |
| VenStrat for predicting benefit from platinum-based chemotherapy agents | UK | UK | (11) Expired / Abandoned | 14/212,567 | 3/14/2014 | | Abandoned | |
| DEEP MALDI | AU | Foreign | (11) Expired / Abandoned | 2013287976 | 3/15/2013 | 2013287976 | Abandoned | 3/15/2016 |
| DEEP MALDI | CA | Foreign | (11) Expired / Abandoned | 2874689 | 3/15/2013 | | Abandoned | |
| DEEP MALDI | CN | Foreign | (11) Expired / Abandoned | 201380029086.3 | 3/15/2013 | | Abandoned | |
| DEEP MALDI | EU | Foreign | (11) Expired / Abandoned | 10715042.3 EP20130715042 | 3/15/2013 | | Abandoned | |
| DEEP MALDI | HK | Foreign | (05) Published | 15108852.3 | 9/10/2015 | | Active | |
| DEEP MALDI | JP | Foreign | (11) Expired / Abandoned | 2013-514792 | 3/15/2013 | | Abandoned | |
| DEEP MALDI | KR | Foreign | (08) Examination Year 3+ | 10-2014-7036612 | 3/15/2013 | | Active | |
| DEEP MALDI | KR | Foreign | (11) Expired / Abandoned | 10-2014-7036612 | 3/15/2013 | | Abandoned | |
| DEEP MALDI | PRO | Foreign | (11) Expired / Abandoned | PCT/US13/13396 | 3/15/2013 | | Abandoned | |
| DEEP MALDI | PRO | US | (11) Expired / Abandoned | 61602394 | 5/29/2012 | | Abandoned | |
| DEEP MALDI | TW | Foreign | (11) Expired / Abandoned | 102112550 | 3/15/2013 | | Abandoned | |
| DEEP MALDI | US | US | (10) Issued / Granted | 13/836,436 | 3/15/2013 | 9,279,798 | Active | 3/8/2016 |
| DEEP MALDI | US | US | (10) Issued / Granted | 14/868,575 | 9/29/2015 | 9,606,101 | Active | 3/28/2017 |
| Mimicking randomized case controlled studies by randomly selecting sample sets from large-scale observational data sets | PRO | UK | (01) Merged into Another Filing | N/A | | | Active | |
| Method for early detection of HCC in patients with liver disease | PRO | US | (02) Merged into Another Filing | N/A | | | Active | |
| BDX001 for selecting GI4000 therapy | AU | Foreign | (08) Examination Year 3+ | 2013281221 | 3/15/2013 | | Active | |
| BDX001 for selecting GI4000 therapy | CA | Foreign | (05) Published | 2878441 | 3/15/2013 | | Active | |
| GI 400 and BDX001 | CN | Foreign | (08) Examination Year 3+ | 201380043182.4, | 3/15/2013 | | Active | |
| BDX001 for selecting GI4000 therapy | EU | Foreign | (11) Expired / Abandoned | 13714124.3 EP20130714324 | 3/15/2013 | | Abandoned | |
| BDX001 for selecting GI4000 therapy | HK | Foreign | (05) Published | 1209835 | 3/15/2011 | | Abandoned | |
| BDX001 for selecting GI4000 therapy | IL | Foreign | (11) Expired / Abandoned | 256256 | 3/15/2013 | | Abandoned | |

| Title | Country | Region / I.P. | Patent Status | Serial No. | Filing Date | Parent No. | Abandoned / Active | Issue Date |
|---|---------|---------------|----------------------------|-------------------|-------------|------------|--------------------|------------|
| BDX001 for selecting GI4000 therapy | JP | Foreign | (08) Examination Year 3+ | 2015-520167 | 3/15/2013 | | Active | |
| BDX001 for selecting GI4000 therapy | KR | Foreign | (04) Non-Provisional Filed | 10-2015-7001998 | 3/15/2013 | | Active | |
| GI 400 and BDX001 | MX | Foreign | | | | | Active | |
| BDX001 for selecting GI4000 therapy | NI | Foreign | (11) Expired / Abandoned | 704089 | 3/15/2013 | | Abandoned | |
| GI 400 and BDX001 | PCT | Foreign | (11) Expired / Abandoned | PCT/US2013/032024 | 3/15/2013 | | Abandoned | |
| GI 400 and BDX001 | PRC | US | (11) Expired / Abandoned | 61,694,329 | 6/26/2012 | | Abandoned | |
| GI 400 and BDX001 | PRD | US | (11) Expired / Abandoned | 61,66,4523 | 6/26/2012 | | Abandoned | |
| BDX001 for selecting GI4000 therapy | SG | Foreign | (06) Examination Year 1 | 112014086525, | 3/15/2013 | | Active | |
| GI 400 and BDX001 | TW | Foreign | (05) Published | 102115975 | 5/3/2013 | | Active | |
| GI 400 and BDX001 | US | US | (09) Allowance | 13/835,909 | 3/15/2013 | | Active | |
| Asthma Early Diagnostic Test | PRO | US | (01) Unfiled | N/A | | | Active | |
| Machine Validator | US | US | (10) Issued / Granted | 13/733,018 | 1/2/2013 | 8,467,988 | Active | 6/18/2013 |
| CMC/D Analytic Methods | AU | Foreign | (06) Examination Year 1 | | | | Active | |
| CMC/D Analytic Methods | CA | Foreign | (11) Expired / Abandoned | CA2324120 | 9/15/2014 | | Abandoned | |
| CMC/D Analytic Methods | CN | Foreign | (11) Expired / Abandoned | CN102746659 | 9/15/2014 | | Abandoned | |
| CMC/D Analytic Methods | RU | Foreign | (11) Expired / Abandoned | EP2647417 | 9/15/2014 | | Abandoned | |
| CMC/D Analytic Methods | PCT | Foreign | (11) Expired / Abandoned | PCT/US14/55635 | 9/15/2014 | | Abandoned | |
| CMC/D Analytic Methods | PRD | US | (11) Expired / Abandoned | 61,876,110 | 9/15/2013 | | Abandoned | |
| CMC/D Analytic Methods | PRO | US | (11) Expired / Abandoned | 61,975,259 | 4/4/2014 | | Abandoned | |
| CMC/D Analytic Methods | TW | Foreign | (05) Published | 103131810 | 9/17/2014 | | Active | |
| CMC/D Analytic Methods | US | US | (10) Issued / Granted | 14/486,442 | 9/15/2014 | 9,477,906 | Active | 10/25/2016 |
| VeriStrat for Ficlatazumab | PCT | Foreign | (11) Expired / Abandoned | PCT/US2015/04250 | 4/3/2015 | | Abandoned | |
| VeriStrat for Ficlatazumab | PRD | US | (11) Expired / Abandoned | 61,376,844 | 4/3/2014 | | Abandoned | |
| VeriStrat for Ficlatazumab | PRO | US | (11) Expired / Abandoned | 61,376,843 | 4/3/2014 | | Abandoned | |
| VeriStrat for Ficlatazumab | PRD | US | (11) Expired / Abandoned | 62,080,611 | 11/17/2014 | | Abandoned | |
| VeriStrat for Ficlatazumab | PRO | US | (11) Expired / Abandoned | 61,026,616 | 11/17/2014 | | Abandoned | |
| VeriStrat for Ficlatazumab | TW | Foreign | (04) Non-Provisional Filed | 104111325 | 4/3/2015 | | Active | |
| VeriStrat for Ficlatazumab | US | US | (11) Expired / Abandoned | 14,678,423 | 4/3/2015 | | Active | |
| VeriStrat 2.0 | CN | Foreign | (05) Published | 201410531233.4, | 10/10/2014 | | Active | |
| VeriStrat 2.0 | PCT | Foreign | (11) Expired / Abandoned | PCT/US14/51247 | 6/15/2014 | | Abandoned | |
| VeriStrat 2.0 | PRD | US | (11) Expired / Abandoned | 61,975,267 | 4/4/2014 | | Abandoned | |
| VeriStrat 2.0 | TW | Foreign | (10) Issued / Granted | 103129746 | 8/28/2014 | 1541674 | Active | 7/11/2016 |
| VeriStrat 2.0 | US | US | (10) Issued / Granted | 14/460,769 | 8/15/2014 | 9,211,314 | Active | 12/15/2015 |
| VeriStrat 2.0 Methods | US | US | (11) Expired / Abandoned | 14,668,615 | 3/25/2015 | | Active | |
| Test for predicting early relapse and guiding treatment in breast | PRC | US | (11) Expired / Abandoned | 62,030,188 | 6/30/2014 | | Abandoned | |
| Test for predicting early relapse and guiding treatment in breast | PRD | US | (11) Expired / Abandoned | 62,031,076 | 6/19/2014 | | Abandoned | |
| Test for predicting early relapse and guiding treatment in breast | US | US | (05) Examination Year 1 | 14,721,662 | 6/5/2015 | | Active | |
| #REF! | EP | | (04) Non-Provisional Filed | 15846544.3 | 9/29/2015 | | | |
| Predictive test for aggressiveness of prostate cancer | PCT | Foreign | (11) Expired / Abandoned | PCT/US2015/022927 | 12/9/2015 | | Active | |
| Predictive test for aggressiveness of prostate cancer | PRC | US | (11) Expired / Abandoned | 62,026,792 | 10/2/2014 | | Abandoned | |
| Predictive test for aggressiveness of prostate cancer | TW | Foreign | (05) Published | 201617030 | 10/2/2015 | | Active | |
| Predictive test for aggressiveness of prostate cancer | US | US | (10) Issued / Granted | 14/869,348 | 9/29/2015 | 9,779,204 | Active | 10/3/2017 |
| #REF! | US | | (06) Examination Year 1 | 15/701,668 | 9/12/2017 | | Active | |
| Test for graft versus host disease | PRC | US | (11) Expired / Abandoned | 62,026,606 | 11/2/2014 | | Abandoned | |

| Title | Country | Region / I.P. | Patent Status | Serial No. | Filing Date | Parent No. | Abandoned / Active | Issue Date |
|---|---------|---------------|----------------------------|-------------------|-------------|------------|--------------------|------------|
| Test for graft-versus-host disease | US | US | (04) Non-Provisional Filed | 14/949,229 | 11/23/2015 | 9,563,744 | Active | 2/7/2017 |
| Early detection of HCC (BDX004) | PCT | Foreign | (11) Expired / Abandoned | PCT/US2015/023065 | 11/19/2015 | | Abandoned | |
| Early detection of HCC (BDX008) | PRG | US | (11) Expired / Abandoned | 62/086,805 | 12/3/2014 | | Abandoned | |
| Early detection of HCC (BDX004) | PW | Foreign | (11) Expired / Abandoned | 104137036 | 11/19/2015 | | Abandoned | |
| Early detection of HCC (BDX008) | US | US | (05) Published | 14/936,847 | 11/10/2015 | | Active | |
| Test for prognosis of myelodysplastic syndrome (MDS) | PRG | US | (11) Expired / Abandoned | 62/086,807 | 12/3/2014 | | Abandoned | |
| Test for prognosis of myelodysplastic syndrome (MDS) | US | US | (06) Examination Year 1 | 14/946,045 | 11/19/2015 | | Active | |
| "bagged filtering" | PRO | US | (11) Expired / Abandoned | PCT/US2015/26046 | 4/5/2016 | | Abandoned | |
| "bagged filtering" | PCT | Foreign | (05) Published | 62/154,844 | 4/30/2015 | | Abandoned | |
| "bagged filtering" | US | US | (04) Non-Provisional Filed | 15/019,417 | 4/4/2016 | | Active | |
| "bagged filtering" | PCT | Foreign | (04) Non-Provisional Filed | 15/019,417 | 4/4/2016 | | Abandoned | |
| Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods | PCT | Foreign | (04) Non-Provisional Filed | PCT/US2016/41860 | 7/12/2016 | | Active | |
| Predictive Test For Patient Benefit From Immunotherapy | PRG | US | (11) Expired / Abandoned | 62/191,895 | 7/13/2015 | | Abandoned | |
| Predictive Test For Patient Benefit From Immunotherapy | PRO | US | (11) Expired / Abandoned | 62/286,587 | 2/3/2016 | | Abandoned | |
| Training of Classifiers Using Subsets of Meta Spectral Features Associated with Biological Functions | PRG | US | (01) Provisional Filed | 62/040,727 | 5/24/2016 | | Active | |
| Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods | US | US | (04) Non-Provisional Filed | 15/207,825 | 7/12/2016 | | Active | |
| Predictive Test for Melanoma Patient Benefit from Interleukin-2 (IL2) therapy | PRO | US | (03) Provisional Filed | 62/369,289 | 2/1/2016 | | Active | |
| Predictive Test for Melanoma Patient Benefit from Interleukin-2 (IL2) therapy | PCT | Foreign | (04) Non-Provisional Filed | PCT/US2017/013920 | 1/18/2017 | | Active | |
| PDL1 Assay | | | (01) Unfiled | | | | Active | |
| Classifier Generation Methods and Predictive Test for Ovarian Cancer Patient Prognosis Under Platinum Chemotherapy | PCT | Foreign | (04) Non-Provisional Filed | PCT/US2017/021736 | 3/10/2017 | | Active | |
| Classifier Generation Methods and Predictive Test for Ovarian Cancer Patient Prognosis Under Platinum | PRG | US | (11) Expired / Abandoned | 62/311,985 | 4/8/2016 | | Abandoned | |
| Pre-treatment Serum Test Identifying Non-Liver Cell Lung Cancer Patient Benefit from Addition of Bevacizumab to Docetaxel | PRG | US | (11) Expired / Abandoned | 62/415,138 | 10/31/2016 | | Active | |
| Durable benefit from immunotherapy in poor prognosis groups | PRO | US | (03) Provisional Filed | 62/442,557 | 1/5/2017 | | Active | |
| Durable benefit from immunotherapy in poor prognosis groups | PCT | Foreign | (04) Non-Provisional Filed | PCT/US2018/012564 | 1/5/2018 | | Active | |
| Diagnostic Test System for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood | US | US | (03) Provisional Filed | 62/442,578 | 1/5/2017 | | Active | |
| Diagnostic Test System for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood | EP | Foreign | (04) Non-Provisional Filed | 18150429.1 | 1/5/2018 | | Active | |

| Title | Country | Applicant / I.P. | Patent Status | Serial No. | Filing Date | Patent No. | Abandoned/Active | Issue Date |
|---|---------|------------------|----------------------------|------------|-------------|------------|------------------|------------|
| Diagnostic Test System for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood | US | US | (04) Non-Provisional Filed | 15/862,896 | 1/5/2018 | | Active | |
| Diagnostic Test System for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood | PRO | US | (01) Unfiled | | | | Active | |
| Diagnostic Test System for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood | PRO | US | (01) Unfiled | | | | Active | |

EXHIBIT C

Trademarks

| <u>Description</u> | <u>Serial/Registration No.</u> | <u>File Date</u> |
|------------------------------------|--------------------------------|--------------------|
| BIODESIX LUNG REFLEX | 5363516 | December 26, 2017 |
| VERISTRAT LIQUID BIOPSY | 87328186 | February 8, 2017 |
| GENESTRAT LIQUID BIOPSY | 87328149 | February 8, 2017 |
| ONCOSTRAT | 87629867 | October 2, 2017 |
| BIODESIX LUNG REFLEX | 87586059 | August 28, 2017 |
| IMMUNOSTRAT | 86588401 | April 6, 2015 |
| DIAGNOSTIC CORTEX | 5087240 | November 22, 2016 |
| GENESTRAT | 5042185 | September 13, 2016 |
| WE THINK FORWARD | 4588638 | August 19, 2014 |
| DEEP MALDI | 4660213 | December 23, 2014 |
| GUIDING THE WAY | 4221851 | October 9, 2012 |
| BIODESIX: MAKING MEDICINE PERSONAL | 4223067 | October 9, 2012 |
| PROTS | 3655592 | July 14, 2009 |
| VERISTRAT | 3470295 | July 22, 2008 |
| BIODESIX | 3483094 | August 12, 2008 |